Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)

NCT04181775 | Completed

• 1 other identifier: 060.PHA.2019.A
• Study Type: observational
• Target: 471
• Locations: 1 country
• Sites: 1

Brief Summary

The rationale for this study is to evaluate the effectiveness of a risk prediction tool for patients who are at high risk for ADEs resulting in hospitalization or ED revisit. The ADE-RED score initiates a PLMR that literature has shown reduces medication discrepancies and ADEs at hospital admission and discharge. No current system identifies patients presenting to the ED that may benefit from PMLR independent of an admission disposition. The ADE-RED scoring tool will reduce the incidence of future visits to the ED or future admissions by identifying patients who are at high risk for ADE-related readmissions.

Conditions

Adverse Drug Event

Outcome Measures

Primary Outcomes (1)

• Incidences of ADE-related readmission within 30 days of prior ED visit.

  Incidences of ADE-related readmission within 30 days of prior ED visit.

  one month period in March 2019

Secondary Outcomes (1)

• Percentage of patients who were readmitted who did or did not have an ADE-RED score at initial ED visit.

  one month period in March 2019

Interventions

ADE-RED scoring tool DIAGNOSTIC_TEST

The ADE-RED scoring tool will reduce the incidence of future visits to the ED or future admissions by identifying patients who are at high risk for ADE-related readmissions.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients are considered high risk if the score is \> 12, moderate risk if the score 6-11, and low risk if the score is 0-5. High-risk patients are flagged in the electronic medical record of the patient, alerting the pharmacist to complete a medication reconciliation and address any issues.

You may qualify if:

• Patients admitted to the hospital with a prior ED visit within the previous 30 days
• Patients presenting to the ED with a prior ED visit within the previous 30 days

You may not qualify if:

• Patients without PTA medications at the time of initial ED presentation

Sponsors & Collaborators

• Methodist Health System: lead

Study Sites (1)

Methodist Dallas Medical Center

Dallas, Texas, 75203, United States

Location

MeSH Terms

Conditions

Drug-Related Side Effects and Adverse Reactions

Condition Hierarchy (Ancestors)

Chemically-Induced Disorders

Study Officials

• Ilka Ratsaphangthong, PharmD

  The Methodist Hospital Research Institute

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 27, 2019
• First Posted: November 29, 2019
• Study Start: November 8, 2019
• Primary Completion: June 22, 2020
• Study Completion: June 22, 2020
• Last Updated: March 24, 2026

Record last verified: 2024-09

Locations

US (1)